2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOCompleted
The primary objective of this study is:After 3 treatment cycles in healthy female subjects between the ages of 18 and 50 years (inclusive): To estimate the effect of the ENG-E2 vaginal ring compared with the LNG-EE COC on hemostatic parameters that…